Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
Recruiting · NCT06724653 · Interventional (participants receive a specific treatment) · Lead sponsor: Chungnam National University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Beta blocker tapering outRAS blocker tapering group
What this trial is about
Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- initial echocardiogram ejection fraction less than 40%
- follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
- NTprobnp criteria
- eGFR ≥60 ; less 440
- eGFR 45-59: less 980
- eGFR 30-44; less 1220
- eGFR \< 30 : less 5300
- in HD; no criteria for NTproBNP
- on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)
Exclusion criteria
- under age 18 year
- uncontrolled BP ( over 150/90)
- coronary revascularization within 6 months
- significant valve disease
- arrhythmia requiring rate control
- CKD with albuminuria ( over 30mg/g)
- Pregnancy
Where it is running
2 locations listed.
- Jeonbuk national university hospital - Jeonju, Jeollabuk-do, South Korea
- Chungnam national university hospital - Daejeon, Republic of Korea, South Korea